Avandia remains the topic of discussion among the advisory panel that was meant to vote for or against Avandia being prescribed as a drug to treat diabetes. The committee recommended that it stays but with stronger warnings and stricter supervision.

It was announced on Wednesday by the Food and Drug Administration advisory committee that the drug should be monitored closely following warnings about the danger of heart attacks.

FDA is expected to reach a decision after considering the committee’s response for several weeks, as the recommendations are not binding.

As far as the members of the committee are concerned, out of 33 members, about 10 members voted to keep Avandia on the market under close supervision, to be continued in the market but with label warnings of a stronger nature, seven voted for it, and three favored the status quo. Removal of the drug from the market was voted by 12 members.

Following evidence that Avandia increases the risk of heart attack, reliance on the drug has dropped.

Dr. Jacob Warman, chief of endocrinology at the Brooklyn Hospital Center in New York, said, “It is expected that the use of the drug would drop further.”